再鼎醫藥
Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com
版塊: Healthcare
行業: Biotechnology
全職員工: 2,175
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 13.27M | 93.65M | 1966 |
| Mr. Joshua L. Smiley | President & COO | 9.56M | 無 | 1970 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Oncology Research & Development | 12.51M | 無 | 1964 |
| Dr. Peter Huang Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
| Ms. Ann E. Beasley J.D. | Chief Compliance Officer | 無 | 無 | 無 |
| Dr. Ning Xu M.D. | Executive VP & Head of Clinical Operations | 無 | 無 | 1965 |
| Dr. Jonathan J. Wang MBA, Ph.D. | Chief Business Officer | 無 | 無 | 1982 |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of R&D | 無 | 無 | 1964 |
| Mr. Yi Liang M.B.A., M.D. | Chief Commercial Officer & President of Greater China | 無 | 無 | 1971 |
描述
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
公司管治
截至 無 止，再鼎醫藥 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
